Mechanistically, we have demonstrated that peroxisome proliferator activated receptor γ (PPARγ) is the direct target of luteolin in the setting of pathological cardiac hypertrophy and the related metabolic disorders. The gene discussed is PPARG; the disease is cardiac hypertrophy.